(Q34763589)

4 August 2017

title

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study (English)

1 reference

4 August 2017

Julia di Iulio

3

0 references

Huldrych F Günthard

object named as

Huldrych F Günthard

12

0 references

Matthias Cavassini

object named as

Matthias Cavassini

6

0 references

Swiss HIV Cohort Study

14

object named as

Swiss HIV Cohort Study

1 reference

4 August 2017

8

Enos Bernasconi

1 reference

4 August 2017

7

Bernard Hirschel

1 reference

4 August 2017

11

Hansjakob Furrer

1 reference

4 August 2017

4

Bruno Ledergerber

1 reference

4 August 2017

13

Amalio Telenti

1 reference

ORCID Public Data File 2021

4 August 2017

1 reference

author name string

Rubin Lubomirov

1

1 reference

4 August 2017

Sara Colombo

2

1 reference

4 August 2017

Raquel Martinez

5

1 reference

4 August 2017

Luigia Elzi

9

1 reference

4 August 2017

Pietro Vernazza

10

1 reference

4 August 2017

language of work or name

English

0 references

publication date

9 December 2010

1 reference

Journal of Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

203

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

246-257

1 reference

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Short-term discontinuation of HAART regimens more common in vulnerable patient populations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

HLA-B*5701 screening for hypersensitivity to abacavir

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Pharmacogenetics of anti-HIV drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Polymorphisms associated with cholesterol and risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Factors associated with efavirenz discontinuation in a large community-based sample of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ043

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Cohort profile: the Swiss HIV Cohort study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071070

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21288825

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cohort studies and the genetics of complex disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21288825

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia: genetic screening is unnecessary

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21288825

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/INFDIS/JIQ043

1 reference

4 August 2017

1 reference

4 August 2017

1 reference